A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kefford, R F, Thomas, N P B, Corrie, P G, Palmer, C, Abdi, E, Kotasek, D, Beith, J, Ranson, M, Mortimer, P, Watson, A J, Margison, G P, Middleton, M R
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2009
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676549/
https://ncbi.nlm.nih.gov/pubmed/19367282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605016
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares